Shield Therapeutics Wins Extra U.S. FDA Exclusivity for ACCRUFeR Pediatric Use

An update from Shield Therapeutics ( (GB:STX) ) is now available.

Shield Therapeutics has secured an additional three years of U.S. FDA data exclusivity for its oral iron therapy ACCRUFeR, extending protection to 19 December 2028 on top of patent coverage into the mid-2030s. The extension follows a new clinical investigation that supported expanding ACCRUFeR’s indication to include pediatric patients aged 10 and older, strengthening the product’s regulatory moat in the key U.S. market.

The broader pediatric indication is underpinned by positive results from the Phase 3 FORTIS trial, which confirmed efficacy, safety and tolerability of a new oral liquid formulation in children as young as one month with iron deficiency anemia. The company says the milestone enhances its ability to grow ACCRUFeR in both adult and pediatric populations, bolstering its competitive position in the fast-growing iron deficiency treatment market and supporting its international commercial strategy.

The most recent analyst rating on (GB:STX) stock is a Sell with a £9.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.

Spark’s Take on GB:STX Stock

According to Spark, TipRanks’ AI Analyst, GB:STX is a Neutral.

The overall stock score is primarily influenced by the company’s robust technical momentum and positive corporate events, which are offset by significant financial challenges and valuation concerns. The strong technical indicators and strategic corporate developments provide optimism, but financial instability remains a critical risk.

To see Spark’s full report on GB:STX stock, click here.

More about Shield Therapeutics

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on treating iron deficiency and iron deficiency anemia with its oral ferric maltol product, marketed as ACCRUFeR in the U.S. and FeRACCRU in other regions. Through partnerships with Viatris and multiple international licensees, the company targets a global iron deficiency market affecting around 20 million people in the U.S. alone, estimated at $2.3 billion.

ACCRUFeR/FeRACCRU is positioned as the first and only FDA-approved oral iron therapy for iron deficiency and iron deficiency anemia, and has become the leading branded prescription oral iron in the U.S. market. The product, protected by patents into the mid-2030s, offers a novel, non-salt-based mechanism of absorption and is commercialised across North America, Europe, Asia-Pacific and selected Asian markets via regional partners.

Average Trading Volume: 2,944,744

Technical Sentiment Signal: Buy

Current Market Cap: £102.5M

For an in-depth examination of STX stock, go to TipRanks’ Overview page.